Three routes stay open when a plan will not pay: the manufacturer’s own self-pay pharmacy for the brand-name product, a supervised practice selling a compounded preparation, and a switch to a molecule the plan already covers. Before pricing any of them, check whether the drug’s second approved indication opens a door the first one closed.
Two approved indications, and coverage follows the indication
The current label lists two uses. The first is reducing excess body weight and maintaining that reduction long term in adults with obesity, or in adults with overweight who have at least one weight-related condition. The second is treating moderate to severe obstructive sleep apnea in adults with obesity. That second use rests on a randomized trial of tirzepatide in adults with OSA and obesity, and the agency described the resulting clearance as the first medication approved for that condition.
The commercial consequence is larger than the clinical one. Pharmacy benefits are written by category. A plan document that excludes drugs for weight loss has excluded a category of use, not a chemical. The same molecule requested for sleep apnea is a different request, judged against different criteria, and sometimes sitting inside a benefit the employer did buy. Whether that holds for one particular plan is answered by that plan’s own documents and nothing else.
Work out which entity is actually answering
Anthem is a Blue Cross Blue Shield licensee. It operates in the states where it holds the license, is run locally rather than as a single national insurer, and sits under the Elevance Health corporate umbrella. Most large employers self-fund their health benefits, meaning the employer pays claims from its own money while the licensee administers the plan on its behalf. In that arrangement the benefit design belongs to the employer.
So a blanket claim in either direction is the wrong shape of statement. The answerable question is what one plan document says, for one indication, in one year. The summary of benefits and coverage, the drug list and the criteria document behind that list are where the answer lives.
Route one: the manufacturer’s self-pay channel
Eli Lilly sells Zepbound to self-paying patients through its own direct pharmacy channel, and Novo Nordisk runs an equivalent for its semaglutide products. These are the approved products, made by the company holding the approval, with the label and supply chain that go with it. Published prices differ by dose and presentation and are revised periodically, so the number to work from is the one on the manufacturer’s page on the day of purchase rather than a figure quoted secondhand.
Route two: a supervised practice selling a compounded preparation
Compounded tirzepatide and compounded semaglutide are prepared by compounding pharmacies. They are not FDA-approved products. The agency does not review them for safety, effectiveness or quality, and it has published specific concerns about unapproved GLP-1 drugs sold for weight loss. A pharmacovigilance analysis of adverse-event reports involving compounded GLP-1 receptor agonists points at dosing and product problems as recurring themes rather than isolated ones.
Cash practices publish monthly program pricing that can be set beside the manufacturer figures. Ro, Hims and Hers, LifeMD and FormBlends all post what a month costs, though what sits inside that month differs sharply: some include the clinician review and the refills, some bill the visit separately, and some quote an introductory rate that steps up later. Reading the second month’s price matters more than reading the first.
Route three: a molecule the plan already pays for
When one drug is excluded and another is not, the cheapest covered option can outperform the best cash price by a wide margin. Semaglutide, liraglutide and older agents sit at different places on different drug lists, and a prescriber can often tell within one call which of them the plan treats as preferred. A head-to-head randomized comparison of semaglutide and tirzepatide exists, so the trade-off can be discussed with real numbers instead of impressions.
| Route | What is being bought | Regulatory status | What drives the real cost |
|---|---|---|---|
| Manufacturer self-pay pharmacy | The approved brand-name product | FDA-approved | Dose, presentation, current list price |
| Supervised compounding practice | A compounded preparation plus clinical oversight | Not FDA-approved | What the monthly fee includes, and month two |
| Covered alternative molecule | A drug the plan already lists | FDA-approved | Tier, deductible position, authorization |
| Second-indication request | The same molecule under the OSA indication | FDA-approved | Diagnostic workup and plan criteria |
Costs that sit outside the medication price
A monthly figure rarely covers everything. Sleep testing, laboratory work, follow-up visits and shipping are billed on their own terms, and any of them can be the item that decides affordability across a year. Where the OSA route is being explored, the diagnostic workup has its own coverage status, and that status is worth confirming before a specialist appointment is booked rather than after.
Transparency about those extra costs varies by provider, which is one reason to read past the headline figure. LillyDirect and NovoCare point buyers to the manufacturer product, while telehealth names such as Henry Meds, Ro and HealthRX each keep their own pages for Zepbound and related options, differing in what the monthly figure absorbs. Setting two or three of those pages side by side shows quickly which one folds in labs, shipping and follow-up and which quotes the drug alone.
Questions people ask
Does an exclusion for weight-loss drugs also block the sleep apnea use?
Not automatically. The two indications are separate, and a category exclusion written around weight loss does not by itself describe a request made for obstructive sleep apnea. Some plan documents write the exclusion around the molecule instead, which closes both doors. Reading the exact exclusion language settles it in a minute.
Is compounded tirzepatide the same drug at a lower price?
No. A compounded preparation has not been through the approval process that reviews a product for safety, effectiveness and quality, and it does not carry the approved product’s label. That is a fact about what is being purchased, and it belongs in the comparison alongside the price.
Do manufacturer savings cards help someone with no coverage?
Often less than expected. Copay assistance is usually built for people who already hold commercial coverage and face cost-sharing, so it can exclude the uninsured and anyone on a public program. The self-pay pharmacy channel is a different mechanism and generally the relevant one here.
How long should a cash route be priced out for?
At least a year. Trial evidence on maintenance shows the treatment effect is tied to continuing therapy, so a program affordable for two months and not for twelve is a different decision from the one that appears at signup. Price the maintenance dose, not the starting dose.
By
